Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy.  Schwarz M, Schwarz C, Schütz A...

Monitoring progress towards elimination of hepatitis B and C in the EU/EEA.  Sharrock KC, Noori T, Axelsson M, Buti M, Diaz A, Fursa O, Hendrickx G, James C, Klavs I, Korenjak M, Maticic M, Mozalevskis A, Peters L, Rigoni R, Rosinska M, Ruut...

Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis.  Manoharan L, Latham NH, Munari SC, Traeger MW, Menon V, Luhmann N, Baggaley R, Macdonald V, Verster A, Siegfried...

Multidisciplinary and Integrated Treatment for Substance Use Disorders and Hepatitis C in an Addiction Treatment Service in India.  Ghosh A, Mahintamani T, Premkumar M, Basu D, Singh V, Duseja A, Subodh Bn, Mohindra R, Sharma A, Arora SK.&nb...

Linkage to hepatitis C treatment in two opioid substitution treatment units in Gothenburg, Sweden: a retrospective cohort study.  Ydreborg M, Lundström E, Kolleby R, Lexén S, Pizarro E, Lindgren J, Wejstål R, Larsson SB.  Subst Abuse T...

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.  Saayman E, Hechter V, Kayuni N, Sonderup MW.  Harm Reduct J. 2023 Mar 4;20(1):27. doi: 10.1186/s12954-023-00759-0. PMID: 36870990; PMCID: ...